Entrepreneur Briefs

Small wonder that Progenics Pharmaceuticals Inc., a 1-year-old company headquartered in Tarrytown, N.Y., is already battling with giants like SmithKline, Genentech, and Biogen in the race to market CD4, a drug that could potentially inhibit the infection of human cells by the AIDS virus. Precociousness is the corporate culture at this startup, whose three founders were all under 30 when they raised their first $1 million to set up operations in April 1988. Terry Burnham, one of the founders,


Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Small wonder that Progenics Pharmaceuticals Inc., a 1-year-old company headquartered in Tarrytown, N.Y., is already battling with giants like SmithKline, Genentech, and Biogen in the race to market CD4, a drug that could potentially inhibit the infection of human cells by the AIDS virus. Precociousness is the corporate culture at this startup, whose three founders were all under 30 when they raised their first $1 million to set up operations in April 1988.

Terry Burnham, one of the founders, recalls that when his partners, Gerard Housey and Paul Maddon, were students in the M.D./Ph.D. program at Columbia University, “they thought about applying the things that they learned to making drugs.” However, Burnham says, the students found that “the academic route wasn’t interesting, because [universities] had to license the drugs out; you couldn’t go all the way.” Before leaving Columbia, Maddon and his academic colleagues developed CD4; this past spring, Progenics ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide